Why AC Immune Stock Skyrocketed Today
Portfolio Pulse from Ryan Gustafson
AC Immune SA (NASDAQ:ACIU) shares surged after the company received FDA Fast Track Designation for its anti-amyloid-beta active immunotherapy, ACI-24.060, for Alzheimer's disease. This follows FDA clearance of the Investigational New Drug application enabling expansion to the USA of the ongoing Phase 1b/2 ABATE study of ACI-24.060. Shares of ACIU were up 78.3% at $3.53 at the time of publication.
June 27, 2023 | 6:49 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AC Immune SA's stock price surged after receiving FDA Fast Track Designation for its Alzheimer's disease immunotherapy, ACI-24.060. This positive regulatory news is likely to continue to drive the stock price in the short term.
The FDA Fast Track Designation is a significant regulatory milestone that can expedite the development and review of a drug. This news is highly relevant and important for AC Immune SA as it validates the potential of their Alzheimer's disease immunotherapy, which could lead to increased investor confidence and a rise in stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100